These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 38540257)

  • 1. Flavonoids as CYP3A4 Inhibitors In Vitro.
    Kondža M; Brizić I; Jokić S
    Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.
    Moon YJ; Wang X; Morris ME
    Toxicol In Vitro; 2006 Mar; 20(2):187-210. PubMed ID: 16289744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids.
    Kondža M; Bojić M; Tomić I; Maleš Ž; Rezić V; Ćavar I
    Molecules; 2021 May; 26(10):. PubMed ID: 34069400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Cytochrome P450 Activities by
    Yim D; Kim MJ; Shin Y; Lee SJ; Shin JG; Kim DH
    Evid Based Complement Alternat Med; 2019; 2019():2673769. PubMed ID: 31001351
    [No Abstract]   [Full Text] [Related]  

  • 5. On the inhibition of cytochrome P450 3A4 by structurally diversified flavonoids.
    Mitrasinovic PM
    J Biomol Struct Dyn; 2022; 40(20):9713-9723. PubMed ID: 34060409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
    Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
    Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
    Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
    Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine.
    Chan WK; Nguyen LT; Miller VP; Harris RZ
    Life Sci; 1998; 62(10):PL135-42. PubMed ID: 9496718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
    Hyland R; Roe EG; Jones BC; Smith DA
    Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.
    Zhou S; Yung Chan S; Cher Goh B; Chan E; Duan W; Huang M; McLeod HL
    Clin Pharmacokinet; 2005; 44(3):279-304. PubMed ID: 15762770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
    Dresser GK; Spence JD; Bailey DG
    Clin Pharmacokinet; 2000 Jan; 38(1):41-57. PubMed ID: 10668858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.
    Zhou SF; Xue CC; Yu XQ; Li C; Wang G
    Ther Drug Monit; 2007 Dec; 29(6):687-710. PubMed ID: 18043468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modeling chemical interaction profiles: II. Molecular docking, spectral data-activity relationship, and structure-activity relationship models for potent and weak inhibitors of cytochrome P450 CYP3A4 isozyme.
    Tie Y; McPhail B; Hong H; Pearce BA; Schnackenberg LK; Ge W; Buzatu DA; Wilkes JG; Fuscoe JC; Tong W; Fowler BA; Beger RD; Demchuk E
    Molecules; 2012 Mar; 17(3):3407-60. PubMed ID: 22421793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavonoids activate pregnane x receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells.
    Dong H; Lin W; Wu J; Chen T
    BMC Biochem; 2010 Jun; 11():23. PubMed ID: 20553580
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Zhang N; Liu J; Chen Z; Dou W
    Pharm Biol; 2019 Dec; 57(1):571-576. PubMed ID: 31456483
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects.
    Li Y; Ning J; Wang Y; Wang C; Sun C; Huo X; Yu Z; Feng L; Zhang B; Tian X; Ma X
    Toxicol Lett; 2018 Sep; 294():27-36. PubMed ID: 29753067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.
    Ohno Y; Hisaka A; Suzuki H
    Clin Pharmacokinet; 2007; 46(8):681-96. PubMed ID: 17655375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Chrysin and Its Major Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide on Cytochrome P450 Enzymes and on OATP, P-gp, BCRP, and MRP2 Transporters.
    Mohos V; Fliszár-Nyúl E; Ungvári O; Bakos É; Kuffa K; Bencsik T; Zsidó BZ; Hetényi C; Telbisz Á; Özvegy-Laczka C; Poór M
    Drug Metab Dispos; 2020 Oct; 48(10):1064-1073. PubMed ID: 32661014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Inhibitory Effect of Flavonoid Aglycones on the Metabolic Activity of CYP3A4 Enzyme.
    Šarić Mustapić D; Debeljak Ž; Maleš Ž; Bojić M
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30301254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of cytochrome P450 3A4 inhibitors
    Pang X; Zhang B; Mu G; Xia J; Xiang Q; Zhao X; Liu A; Du G; Cui Y
    RSC Adv; 2018 Oct; 8(61):34783-34792. PubMed ID: 35547066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.